… the first tumor necrosis factor-ɑ (TNF-α) inhibitor to be approved for the treatment of juvenile
… the same year infliximab was approved for the treatment of Crohn’s disease. Several other …

… for latent TB infection (LTBI) prior to initiating treatment with TNFi. If patients develop active
TB while on treatment with a TNFi, it should be stopped, and TB treatment should be started …

… associating MGCs reduction and tuberculosis reactivation upon treatment with TNF-α
blockers. We also observed a decrease of MGCs upon adalimumab treatment. Reduction of …

… The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET …
in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: a meta-…

… Tuberculosis (TB) is a common complication associated with treatment with tumour necrosis
factor (TNF) antagonists … risk of TB relapse in patients with TB and comorbidities requiring …

… infection and tuberculosis pathogenesis depend on the … cyto ine profile, including tumor
necrosis factor (TNF). The … sis related to tumour necrosis factor antagonist therapies: A TBNET …

… taking tumor necrosis factor blockers. J Rheumatol. 2011;38(10):2218-23. … tuberculosis
among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. …

… TB associated with the use of tumor necrosis factor (TNF) inhibitors, which are increasingly
prescribed as therapy … clinical setting and the type of TNF antagonist used [20]. Most cases of …

… risk of patients due to the biologic’s immune suppressive activity is to compare patients with
documented LTBI who had been administered the relevant … the risk of TB between treatment (…

… ): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34(4):706-11. …
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET …